IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer
Joonbeom Bae, Longchao Liu, Casey Moore, Eric J. Hsu, Anli Zhang, Zhenhua Ren, Zhichen Sun, Xue Wang, Jiankun Zhu, Jiao Shen, Jian Qiao, Yang‐Xin Fu
Topics & Concepts
Mesenchymal stem cellImmunotherapyCancer immunotherapyCancer researchCD8Cell biologyCancerCytotoxic T cellImmunologyBiologyImmune systemBiochemistryIn vitroGeneticsCancer Immunotherapy and BiomarkersMesenchymal stem cell researchImmunotherapy and Immune Responses